Search - tctmd.com

Displaying 121 - 140 of 224

Sort: Relevancy | Date

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Advertisement

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Recurrent Events Common Among Young Patients With CAD

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

CHD Mortality Significantly Elevated in Patients With Severe FH

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content